midazolam has been researched along with Innate Inflammatory Response in 30 studies
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To prospectively study the relationship between inflammation, organ failure, and midazolam clearance as a validated marker of CYP3A-mediated drug metabolism in critically ill children." | 9.22 | Inflammation and Organ Failure Severely Affect Midazolam Clearance in Critically Ill Children. ( Brussee, JM; de Hoog, M; de Wildt, SN; Jerchel, IS; Knibbe, CA; Koch, BC; Mooij, MG; Tibboel, D; van Schaik, RH; Verlaat, CW; Vet, NJ, 2016) |
| "To investigate and compare the effects of propofol and midazolam on inflammation and oxidase stress in children with congenital heart disease undergoing cardiac surgery." | 9.15 | Comparison of the effects of propofol and midazolam on inflammation and oxidase stress in children with congenital heart disease undergoing cardiac surgery. ( Liu, Y; Tang, QZ; Xia, WF; Zhou, QS; Zou, HD, 2011) |
| "Inflammation, reflected by high IL-6, reduces midazolam clearance in critically ill patients with COVID-19." | 8.12 | Hyperinflammation Reduces Midazolam Metabolism in Critically Ill Adults with COVID-19. ( Endeman, H; Gommers, DAMPJ; Hunfeld, NGM; Koch, BCP; Sassen, SDT; Smeets, TJL; Valkenburg, AJ; van der Jagt, M, 2022) |
| "Altered physiology caused by critical illness may change midazolam pharmacokinetics and thereby result in adverse reactions and outcomes in this vulnerable patient population." | 8.12 | Inflammation and cardiovascular status impact midazolam pharmacokinetics in critically ill children: An observational, prospective, controlled study. ( Austin, R; Mulla, H; Neupane, B; Pandya, H; Pandya, T; Rudge, J; Spooner, N, 2022) |
| "To investigate influence of inflammation on metabolism and pharmacokinetics (PK) of midazolam (MDZ) and construct a semi-physiologically based pharmacokinetic (PBPK) model to predict PK in mice with inflammatory disease." | 7.88 | A Semi-Physiologically Based Pharmacokinetic Model Describing the Altered Metabolism of Midazolam Due to Inflammation in Mice. ( Chang, W; Forrest, ML; Patel, N; Ruterbories, K; Varkhede, N, 2018) |
| "Exposure to chemical warfare nerve agents (CWNAs), such as soman (GD), can induce status epilepticus (SE) that becomes refractory to benzodiazepines when treatment is delayed, leading to increased risk of epileptogenesis, severe neuropathology, and long-term behavioral and cognitive deficits." | 7.88 | Soman-induced status epilepticus, epileptogenesis, and neuropathology in carboxylesterase knockout mice treated with midazolam. ( de Araujo Furtado, M; Du, F; Kundrick, E; Lumley, LA; Marrero-Rosado, B; O'Brien, S; Schultz, CR; Stone, M; Walker, K, 2018) |
| "The effect of carrageenan-induced acute peripheral inflammation (API) on the pharmacokinetics of the hepatically metabolizing compound midazolam (MDZ) was investigated in rats." | 7.80 | Effect of carrageenan-induced acute peripheral inflammation on the pharmacokinetics and hepatic metabolism of midazolam in rats. ( Aiba, T; Doi, M; Kajikawa, N; Kusaba, J, 2014) |
| "In 99 patients receiving IV fentanyl, midazolam, or both, we evaluated drug doses, covariates likely to influence drug effects (age, body mass index, and renal and hepatic dysfunction); delirium risk factors; concomitant administration of CYP3A and P-glycoprotein substrates/inhibitors; ABCB1, ABCG2, and CYP3A5 genetic polymorphisms; and fentanyl and midazolam plasma levels." | 7.79 | Factors predisposing to coma and delirium: fentanyl and midazolam exposure; CYP3A5, ABCB1, and ABCG2 genetic polymorphisms; and inflammatory factors. ( Cossette, M; Leger, C; Michaud, V; Skrobik, Y; Turgeon, J, 2013) |
| "To determine the effect of inflammation and disease severity on midazolam pharmacokinetics (as surrogate marker of cytochrome 3A activity) and pharmacodynamics in critically ill children." | 7.78 | The effect of critical illness and inflammation on midazolam therapy in children. ( de Hoog, M; de Wildt, SN; Tibboel, D; Vet, NJ, 2012) |
| "In both acute thermal- and inflammatory-induced pain, intrathecally administered midazolam and bupivacaine produced synergistic analgesia with decreased side effects in intrathecally catheterized rats." | 7.72 | Midazolam can potentiate the analgesic effects of intrathecal bupivacaine on thermal- or inflammatory-induced pain. ( Hanaoka, K; Nishiyama, T, 2003) |
| "Spinally-administered midazolam, a benzodiazepine, and clonidine, an alpha2-adrenergic receptor agonist, have significant synergistic effects on thermally-induced acute and formalin-induced inflammatory pain." | 7.71 | The synergistic interaction between midazolam and clonidine in spinally-mediated analgesia in two different pain models of rats. ( Hanaoka, K; Nishiyama, T, 2001) |
| "Midazolam controlled seizures, neurodegeneration, and neuroinflammation when given early (10 minutes) after DFP exposure, but it was less effective when given at 40 minutes or later." | 5.48 | Midazolam-Resistant Seizures and Brain Injury after Acute Intoxication of Diisopropylfluorophosphate, an Organophosphate Pesticide and Surrogate for Nerve Agents. ( Kuruba, R; Reddy, DS; Wu, X, 2018) |
| "To prospectively study the relationship between inflammation, organ failure, and midazolam clearance as a validated marker of CYP3A-mediated drug metabolism in critically ill children." | 5.22 | Inflammation and Organ Failure Severely Affect Midazolam Clearance in Critically Ill Children. ( Brussee, JM; de Hoog, M; de Wildt, SN; Jerchel, IS; Knibbe, CA; Koch, BC; Mooij, MG; Tibboel, D; van Schaik, RH; Verlaat, CW; Vet, NJ, 2016) |
| "The aim of the study was to determine whether or not dexmedetomidine- (DEX-) based intravenous infusion in dental implantation can provide better sedation and postoperative analgesia via suppressing postoperative inflammation and oxidative stress." | 5.20 | Dexmedetomidine Analgesia Effects in Patients Undergoing Dental Implant Surgery and Its Impact on Postoperative Inflammatory and Oxidative Stress. ( Cheung, CW; Li, S; Qian, L; Wu, Y; Yang, Y; Yao, Y; Yu, C, 2015) |
| "To investigate and compare the effects of propofol and midazolam on inflammation and oxidase stress in children with congenital heart disease undergoing cardiac surgery." | 5.15 | Comparison of the effects of propofol and midazolam on inflammation and oxidase stress in children with congenital heart disease undergoing cardiac surgery. ( Liu, Y; Tang, QZ; Xia, WF; Zhou, QS; Zou, HD, 2011) |
| "Inflammation, reflected by high IL-6, reduces midazolam clearance in critically ill patients with COVID-19." | 4.12 | Hyperinflammation Reduces Midazolam Metabolism in Critically Ill Adults with COVID-19. ( Endeman, H; Gommers, DAMPJ; Hunfeld, NGM; Koch, BCP; Sassen, SDT; Smeets, TJL; Valkenburg, AJ; van der Jagt, M, 2022) |
| "Altered physiology caused by critical illness may change midazolam pharmacokinetics and thereby result in adverse reactions and outcomes in this vulnerable patient population." | 4.12 | Inflammation and cardiovascular status impact midazolam pharmacokinetics in critically ill children: An observational, prospective, controlled study. ( Austin, R; Mulla, H; Neupane, B; Pandya, H; Pandya, T; Rudge, J; Spooner, N, 2022) |
| "To investigate influence of inflammation on metabolism and pharmacokinetics (PK) of midazolam (MDZ) and construct a semi-physiologically based pharmacokinetic (PBPK) model to predict PK in mice with inflammatory disease." | 3.88 | A Semi-Physiologically Based Pharmacokinetic Model Describing the Altered Metabolism of Midazolam Due to Inflammation in Mice. ( Chang, W; Forrest, ML; Patel, N; Ruterbories, K; Varkhede, N, 2018) |
| "Exposure to chemical warfare nerve agents (CWNAs), such as soman (GD), can induce status epilepticus (SE) that becomes refractory to benzodiazepines when treatment is delayed, leading to increased risk of epileptogenesis, severe neuropathology, and long-term behavioral and cognitive deficits." | 3.88 | Soman-induced status epilepticus, epileptogenesis, and neuropathology in carboxylesterase knockout mice treated with midazolam. ( de Araujo Furtado, M; Du, F; Kundrick, E; Lumley, LA; Marrero-Rosado, B; O'Brien, S; Schultz, CR; Stone, M; Walker, K, 2018) |
| "Inflammation was induced by injecting poly(I:C) (pIC 10 mg/kg, postnatal day 12-14), seizure was induced by injecting pilocarpine hydrochloride (PILO 200 mg/kg, postnatal day 15) into C57BL/6J mice, and the pIC+PILO mice were used as the iSE model (miSE)." | 3.81 | Benzodiazepines induce sequelae in immature mice with inflammation-induced status epilepticus. ( Hirai, S; Morio, T; Nakajima, K; Okado, H, 2015) |
| "The effect of carrageenan-induced acute peripheral inflammation (API) on the pharmacokinetics of the hepatically metabolizing compound midazolam (MDZ) was investigated in rats." | 3.80 | Effect of carrageenan-induced acute peripheral inflammation on the pharmacokinetics and hepatic metabolism of midazolam in rats. ( Aiba, T; Doi, M; Kajikawa, N; Kusaba, J, 2014) |
| "In 99 patients receiving IV fentanyl, midazolam, or both, we evaluated drug doses, covariates likely to influence drug effects (age, body mass index, and renal and hepatic dysfunction); delirium risk factors; concomitant administration of CYP3A and P-glycoprotein substrates/inhibitors; ABCB1, ABCG2, and CYP3A5 genetic polymorphisms; and fentanyl and midazolam plasma levels." | 3.79 | Factors predisposing to coma and delirium: fentanyl and midazolam exposure; CYP3A5, ABCB1, and ABCG2 genetic polymorphisms; and inflammatory factors. ( Cossette, M; Leger, C; Michaud, V; Skrobik, Y; Turgeon, J, 2013) |
| "To determine the effect of inflammation and disease severity on midazolam pharmacokinetics (as surrogate marker of cytochrome 3A activity) and pharmacodynamics in critically ill children." | 3.78 | The effect of critical illness and inflammation on midazolam therapy in children. ( de Hoog, M; de Wildt, SN; Tibboel, D; Vet, NJ, 2012) |
| "We conclude that decreased cerebral endothelial ICAM-1 expression in response to activated glial cell compartment by midazolam may decrease post ischaemic brain inflammation and secondary brain injury." | 3.73 | Effect of midazolam on in vitro cerebral endothelial ICAM-1 expression induced by astrocyte-conditioned medium. ( Ghori, K; Harmon, D; Shorten, G; Walsh, F, 2006) |
| "In both acute thermal- and inflammatory-induced pain, intrathecally administered midazolam and bupivacaine produced synergistic analgesia with decreased side effects in intrathecally catheterized rats." | 3.72 | Midazolam can potentiate the analgesic effects of intrathecal bupivacaine on thermal- or inflammatory-induced pain. ( Hanaoka, K; Nishiyama, T, 2003) |
| "Spinally-administered midazolam, a benzodiazepine, and clonidine, an alpha2-adrenergic receptor agonist, have significant synergistic effects on thermally-induced acute and formalin-induced inflammatory pain." | 3.71 | The synergistic interaction between midazolam and clonidine in spinally-mediated analgesia in two different pain models of rats. ( Hanaoka, K; Nishiyama, T, 2001) |
| "Spinally administered midazolam, even in large doses, does not cause acute neurotoxicity or inflammation of the spinal cord." | 3.70 | Acute phase histopathological study of spinally administered midazolam in cats. ( Hanaoka, K; Matsukawa, T; Nishiyama, T, 1999) |
| "Xenobiotics can interact with cytochromes P450 (CYPs), resulting in drug-drug interactions, but CYPs can also contribute to drug-disease interactions, especially in the case of inflammation, which downregulates CYP activities through pretranscriptional and posttranscriptional mechanisms." | 1.72 | Prediction of cytochromes P450 3A and 2C19 modulation by both inflammation and drug interactions using physiologically based pharmacokinetics. ( Daali, Y; Desmeules, JA; Lenoir, C; Niederer, A; Rollason, V; Samer, CF, 2022) |
| "For decades, inflammation has been considered a cause of pharmacokinetic variability, mainly in relation to the inhibitory effect of pro-inflammatory cytokines on the expression level and activity of cytochrome P450 (CYP)." | 1.62 | Modeling Approach to Predict the Impact of Inflammation on the Pharmacokinetics of CYP2C19 and CYP3A4 Substrates. ( Chenel, M; Gautier-Veyret, E; Payen, L; Simon, F; Stanke-Labesque, F; Tod, M; Truffot, A, 2021) |
| "Midazolam controlled seizures, neurodegeneration, and neuroinflammation when given early (10 minutes) after DFP exposure, but it was less effective when given at 40 minutes or later." | 1.48 | Midazolam-Resistant Seizures and Brain Injury after Acute Intoxication of Diisopropylfluorophosphate, an Organophosphate Pesticide and Surrogate for Nerve Agents. ( Kuruba, R; Reddy, DS; Wu, X, 2018) |
| "Mice treated with midazolam had significantly lower serum IL-1β (p=0." | 1.38 | The burn wound inflammatory response is influenced by midazolam. ( Babcock, GF; Dugan, A; Hernandez, L; Schwemberger, S; Yadav, E, 2012) |
| "Centrally mediated seizures are a common consequence of exposure to organophosphates (OP) despite conventional treatment with atropine and an oxime." | 1.33 | Seizure duration following sarin exposure affects neuro-inflammatory markers in the rat brain. ( Chapman, S; Gilat, E; Kadar, T, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.33) | 18.2507 |
| 2000's | 7 (23.33) | 29.6817 |
| 2010's | 16 (53.33) | 24.3611 |
| 2020's | 6 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lenoir, C | 2 |
| Rodieux, F | 1 |
| Desmeules, JA | 2 |
| Rollason, V | 2 |
| Samer, CF | 2 |
| Niederer, A | 1 |
| Daali, Y | 1 |
| Smeets, TJL | 1 |
| Valkenburg, AJ | 1 |
| van der Jagt, M | 1 |
| Koch, BCP | 1 |
| Endeman, H | 1 |
| Gommers, DAMPJ | 1 |
| Sassen, SDT | 1 |
| Hunfeld, NGM | 1 |
| Neupane, B | 1 |
| Pandya, H | 1 |
| Pandya, T | 1 |
| Austin, R | 1 |
| Spooner, N | 1 |
| Rudge, J | 1 |
| Mulla, H | 1 |
| Dunvald, AD | 1 |
| Søltoft, K | 1 |
| Sheetal, E | 1 |
| Just, SA | 1 |
| Frederiksen, IEB | 1 |
| Nielsen, F | 1 |
| Olsen, DA | 1 |
| Madsen, JS | 1 |
| Hendricks, O | 1 |
| Stage, TB | 1 |
| Simon, F | 1 |
| Gautier-Veyret, E | 1 |
| Truffot, A | 1 |
| Chenel, M | 1 |
| Payen, L | 1 |
| Stanke-Labesque, F | 1 |
| Tod, M | 1 |
| Varkhede, N | 1 |
| Patel, N | 1 |
| Chang, W | 1 |
| Ruterbories, K | 1 |
| Forrest, ML | 1 |
| Wu, X | 1 |
| Kuruba, R | 1 |
| Reddy, DS | 1 |
| Marrero-Rosado, B | 1 |
| de Araujo Furtado, M | 1 |
| Schultz, CR | 1 |
| Stone, M | 1 |
| Kundrick, E | 1 |
| Walker, K | 1 |
| O'Brien, S | 1 |
| Du, F | 1 |
| Lumley, LA | 1 |
| Horiguchi, Y | 1 |
| Ohta, N | 1 |
| Yamamoto, S | 1 |
| Koide, M | 1 |
| Fujino, Y | 1 |
| Kajikawa, N | 1 |
| Doi, M | 1 |
| Kusaba, J | 1 |
| Aiba, T | 1 |
| Cai, Y | 1 |
| Li, Y | 1 |
| Ji, M | 1 |
| Yang, H | 1 |
| Zhang, Q | 1 |
| Jin, Z | 1 |
| Coutant, DE | 1 |
| Kulanthaivel, P | 1 |
| Turner, PK | 1 |
| Bell, RL | 1 |
| Baldwin, J | 1 |
| Wijayawardana, SR | 1 |
| Pitou, C | 1 |
| Hall, SD | 1 |
| Li, S | 1 |
| Yang, Y | 1 |
| Yu, C | 1 |
| Yao, Y | 1 |
| Wu, Y | 1 |
| Qian, L | 1 |
| Cheung, CW | 1 |
| Nakajima, K | 1 |
| Hirai, S | 1 |
| Morio, T | 1 |
| Okado, H | 1 |
| Vet, NJ | 2 |
| Brussee, JM | 1 |
| de Hoog, M | 2 |
| Mooij, MG | 1 |
| Verlaat, CW | 1 |
| Jerchel, IS | 1 |
| van Schaik, RH | 1 |
| Koch, BC | 1 |
| Tibboel, D | 2 |
| Knibbe, CA | 1 |
| de Wildt, SN | 2 |
| Nishiyama, T | 4 |
| Xia, WF | 1 |
| Liu, Y | 1 |
| Zhou, QS | 1 |
| Tang, QZ | 1 |
| Zou, HD | 1 |
| Babcock, GF | 1 |
| Hernandez, L | 1 |
| Yadav, E | 1 |
| Schwemberger, S | 1 |
| Dugan, A | 1 |
| Poloyac, SM | 1 |
| Gandhi, AS | 1 |
| Guo, T | 1 |
| Shah, P | 1 |
| Moorthy, B | 1 |
| Chow, DS | 1 |
| Hu, M | 1 |
| Ghose, R | 1 |
| Skrobik, Y | 1 |
| Leger, C | 1 |
| Cossette, M | 1 |
| Michaud, V | 1 |
| Turgeon, J | 1 |
| Hanaoka, K | 3 |
| Chapman, S | 1 |
| Kadar, T | 1 |
| Gilat, E | 1 |
| Ghori, K | 1 |
| Harmon, D | 1 |
| Walsh, F | 1 |
| Shorten, G | 1 |
| Sharma, R | 1 |
| Kacevska, M | 1 |
| London, R | 1 |
| Clarke, SJ | 1 |
| Liddle, C | 1 |
| Robertson, G | 1 |
| Anseloni, VC | 1 |
| Gold, MS | 1 |
| Matsukawa, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Remimazolam on Incidence of Postoperative Nausea and Vomiting Following General Anesthesia in High-risk Patients: a Multicenter, Double-blinded, Placebo-controlled Randomized Trial[NCT04861337] | Phase 4 | 552 participants (Actual) | Interventional | 2021-05-19 | Completed | ||
| Demonstration of OTC Naproxen Sodium's (Aleve's) Anti-inflammatory Action in Dental Implant Surgery Patients[NCT04694300] | Phase 4 | 32 participants (Actual) | Interventional | 2021-02-07 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for midazolam and Innate Inflammatory Response
| Article | Year |
|---|---|
Impact of Inflammation on Cytochromes P450 Activity in Pediatrics: A Systematic Review.
Topics: Adult; Child; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Inflammation; Midazolam; Pe | 2021 |
Understanding Disease-Drug Interactions in Cancer Patients: Implications for Dosing Within the Therapeutic Window.
Topics: Acute-Phase Proteins; Cytochrome P-450 Enzyme System; Cytokines; Drug Interactions; Humans; Imidazol | 2015 |
4 trials available for midazolam and Innate Inflammatory Response
| Article | Year |
|---|---|
[The effect of mild sedation on the prognosis and inflammatory markers in critical patients with mechanical ventilation].
Topics: Biomarkers; Critical Illness; Humans; Hypnotics and Sedatives; Inflammation; Intensive Care Units; I | 2014 |
Dexmedetomidine Analgesia Effects in Patients Undergoing Dental Implant Surgery and Its Impact on Postoperative Inflammatory and Oxidative Stress.
Topics: Adult; Analgesics, Non-Narcotic; Dental Implants; Dexmedetomidine; Enzyme-Linked Immunosorbent Assay | 2015 |
Inflammation and Organ Failure Severely Affect Midazolam Clearance in Critically Ill Children.
Topics: Adolescent; Anesthetics, Intravenous; Child; Child, Preschool; Critical Illness; Female; Humans; Inf | 2016 |
Comparison of the effects of propofol and midazolam on inflammation and oxidase stress in children with congenital heart disease undergoing cardiac surgery.
Topics: Anesthesia, Intravenous; Anesthetics, Intravenous; Cardiac Surgical Procedures; Child; Female; Heart | 2011 |
24 other studies available for midazolam and Innate Inflammatory Response
| Article | Year |
|---|---|
Prediction of cytochromes P450 3A and 2C19 modulation by both inflammation and drug interactions using physiologically based pharmacokinetics.
Topics: Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P- | 2022 |
Hyperinflammation Reduces Midazolam Metabolism in Critically Ill Adults with COVID-19.
Topics: Adult; COVID-19 Drug Treatment; Critical Illness; Cytochrome P-450 CYP3A; Humans; Hypnotics and Seda | 2022 |
Inflammation and cardiovascular status impact midazolam pharmacokinetics in critically ill children: An observational, prospective, controlled study.
Topics: C-Reactive Protein; Child; Critical Illness; Humans; Inflammation; Midazolam; Prospective Studies | 2022 |
Cytochrome P450 activity in rheumatoid arthritis patients during continuous IL-6 receptor antagonist therapy.
Topics: Arthritis, Rheumatoid; Cholesterol; Cytochrome P-450 CYP3A; Humans; Inflammation; Midazolam; Recepto | 2023 |
Modeling Approach to Predict the Impact of Inflammation on the Pharmacokinetics of CYP2C19 and CYP3A4 Substrates.
Topics: Antifungal Agents; Computer Simulation; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome | 2021 |
A Semi-Physiologically Based Pharmacokinetic Model Describing the Altered Metabolism of Midazolam Due to Inflammation in Mice.
Topics: Adjuvants, Anesthesia; Animals; Cytochrome P-450 CYP3A; Glucose-6-Phosphate Isomerase; Humans; Infla | 2018 |
Midazolam-Resistant Seizures and Brain Injury after Acute Intoxication of Diisopropylfluorophosphate, an Organophosphate Pesticide and Surrogate for Nerve Agents.
Topics: Animals; Anticonvulsants; Benzodiazepines; Brain; Brain Injuries; Cholinesterase Inhibitors; Drug Re | 2018 |
Soman-induced status epilepticus, epileptogenesis, and neuropathology in carboxylesterase knockout mice treated with midazolam.
Topics: Animals; Anticonvulsants; Carboxylesterase; Cell Count; Chemical Warfare Agents; Cholinesterase Reac | 2018 |
Midazolam suppresses the lipopolysaccharide-stimulated immune responses of human macrophages via translocator protein signaling.
Topics: Animals; Anti-Inflammatory Agents; Humans; Inflammation; Interleukin-10; Interleukin-6; Lipopolysacc | 2019 |
Effect of carrageenan-induced acute peripheral inflammation on the pharmacokinetics and hepatic metabolism of midazolam in rats.
Topics: Animals; Carrageenan; Cytochrome P-450 CYP3A; Female; Inflammation; Liver; Male; Midazolam; Rats; Ra | 2014 |
Benzodiazepines induce sequelae in immature mice with inflammation-induced status epilepticus.
Topics: Animals; Anticonvulsants; Apoptosis; Benzodiazepines; Convulsants; Exploratory Behavior; GABA Agonis | 2015 |
Interaction between midazolam and serotonin in spinally mediated antinociception in rats.
Topics: Analgesics; Animals; Behavior, Animal; Dose-Response Relationship, Drug; Formaldehyde; GABA Agonists | 2009 |
The effect of critical illness and inflammation on midazolam therapy in children.
Topics: Adolescent; C-Reactive Protein; Child; Child, Preschool; Cohort Studies; Critical Illness; Cytokines | 2012 |
The burn wound inflammatory response is influenced by midazolam.
Topics: Animals; Burns; Chemokine CCL2; Chemokine CCL3; Chemokine CCL4; Chemokine CXCL2; Inflammation; Inter | 2012 |
Altered drug metabolism in critically ill children: a significant source of adverse effects?.
Topics: Critical Illness; Female; Humans; Inflammation; Male; Midazolam; Multiple Organ Failure | 2012 |
CYP3A-dependent drug metabolism is reduced in bacterial inflammation in mice.
Topics: Anesthetics, Intravenous; Animals; Cytochrome P-450 CYP3A; Inflammation; Lipopolysaccharides; Male; | 2012 |
Factors predisposing to coma and delirium: fentanyl and midazolam exposure; CYP3A5, ABCB1, and ABCG2 genetic polymorphisms; and inflammatory factors.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member | 2013 |
Midazolam can potentiate the analgesic effects of intrathecal bupivacaine on thermal- or inflammatory-induced pain.
Topics: Anesthetics, Intravenous; Anesthetics, Local; Animals; Behavior, Animal; Bupivacaine; Dose-Response | 2003 |
Seizure duration following sarin exposure affects neuro-inflammatory markers in the rat brain.
Topics: Animals; Anticonvulsants; Brain Chemistry; Chemical Warfare Agents; Cholinesterase Inhibitors; Cytok | 2006 |
Effect of midazolam on in vitro cerebral endothelial ICAM-1 expression induced by astrocyte-conditioned medium.
Topics: Anesthetics, Intravenous; Animals; Astrocytes; Brain; Culture Media, Conditioned; Endothelial Cells; | 2006 |
Downregulation of drug transport and metabolism in mice bearing extra-hepatic malignancies.
Topics: Acute-Phase Proteins; Animals; Anti-Anxiety Agents; ATP Binding Cassette Transporter, Subfamily B; A | 2008 |
Inflammation-induced shift in the valence of spinal GABA-A receptor-mediated modulation of nociception in the adult rat.
Topics: Animals; Antineoplastic Agents; Flumazenil; Freund's Adjuvant; GABA Agonists; GABA Antagonists; GABA | 2008 |
Acute phase histopathological study of spinally administered midazolam in cats.
Topics: Acute-Phase Reaction; Adjuvants, Anesthesia; Animals; Atrophy; Cats; Inflammation; Injections, Spina | 1999 |
The synergistic interaction between midazolam and clonidine in spinally-mediated analgesia in two different pain models of rats.
Topics: Adrenergic alpha-Agonists; Analgesia; Anesthetics, Intravenous; Animals; Behavior, Animal; Clonidine | 2001 |